PSMA-SPECT/CT also demonstrated higher sensitivity than BS with SPECT/CT and MRI for the detection of skeletal metastases in patients with biochemical recurrence of prostate cancer [92]. This evidence concerns the gene FOLH1 and prostate carcinoma.